Keith Colaco1, Jessica Widdifield2, Jin Luo3, Cheryl F Rosen4, Raed Alhusayen5, J Michael Paterson6, Willemina Campbell4, Karen Tu7, Sasha Bernatsky8, Dafna D Gladman4, Lihi Eder9. 1. Women's College Hospital, Toronto, Canada; University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada. 2. University of Toronto, Toronto, Canada; ICES, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada. 3. ICES, Toronto, Canada. 4. University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada. 5. University of Toronto, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada. 6. University of Toronto, Toronto, Canada; ICES, Toronto, Canada. 7. University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada; North York General Hospital, Toronto, Canada. 8. McGill University, Montréal, Canada. 9. Women's College Hospital, Toronto, Canada; University of Toronto, Toronto, Canada. Electronic address: lihi.eder@wchospital.ca.
Abstract
BACKGROUND: There is limited information about mortality rates among patients with psoriasis and psoriatic arthritis (PsA) in North America and their change over the past 2 decades. OBJECTIVE: To compare all-cause and cause-specific mortality rates in patients with psoriasis to the general population in Ontario, Canada, from 1996 to 2016. METHODS: We conducted a population-based, retrospective cohort study of adult residents using administrative health data. All-cause and cause-specific standardized mortality rates, standardized mortality ratios, and excess mortality rates were calculated. RESULTS: 176,858 (2,524 deaths) patients with psoriasis and 15,430 (221 deaths) patients with PsA were identified in 2016. Patients with psoriasis and PsA had standardized excess mortality rates of 1.44 and 2.43 per 1000 population, respectively. Standardized mortality rates decreased by approximately 30% over the study period in both disease groups but remained significantly elevated compared to the general population. The leading causes of death in psoriasis and PsA patients were cancer, circulatory disease, and respiratory conditions. LIMITATIONS: We were unable to classify patients according to disease severity. CONCLUSIONS: Despite improvements in psoriasis treatment, the relative excess mortality, which may be related to risk factors for psoriatic disease, remained unchanged, with an average of approximately 1 to 2 extra deaths per 1,000 patients in 2016.
BACKGROUND: There is limited information about mortality rates among patients with psoriasis and psoriatic arthritis (PsA) in North America and their change over the past 2 decades. OBJECTIVE: To compare all-cause and cause-specific mortality rates in patients with psoriasis to the general population in Ontario, Canada, from 1996 to 2016. METHODS: We conducted a population-based, retrospective cohort study of adult residents using administrative health data. All-cause and cause-specific standardized mortality rates, standardized mortality ratios, and excess mortality rates were calculated. RESULTS: 176,858 (2,524 deaths) patients with psoriasis and 15,430 (221 deaths) patients with PsA were identified in 2016. Patients with psoriasis and PsA had standardized excess mortality rates of 1.44 and 2.43 per 1000 population, respectively. Standardized mortality rates decreased by approximately 30% over the study period in both disease groups but remained significantly elevated compared to the general population. The leading causes of death in psoriasis and PsA patients were cancer, circulatory disease, and respiratory conditions. LIMITATIONS: We were unable to classify patients according to disease severity. CONCLUSIONS: Despite improvements in psoriasis treatment, the relative excess mortality, which may be related to risk factors for psoriatic disease, remained unchanged, with an average of approximately 1 to 2 extra deaths per 1,000 patients in 2016.
Authors: Haseeb Chaudhary; Nidrit Bohra; Khezar Syed; Anthony Donato; M Hassan Murad; Paras Karmacharya Journal: Arthritis Care Res (Hoboken) Date: 2021-11-17 Impact factor: 5.178
Authors: Jolanta Dadonienė; Greta Charukevič; Gabija Jasionytė; Karolina Staškuvienė; Dalia Miltinienė Journal: Int J Environ Res Public Health Date: 2021-11-24 Impact factor: 3.390
Authors: Keith Colaco; Ker-Ai Lee; Shadi Akhtari; Raz Winer; Paul Welsh; Naveed Sattar; Iain B McInnes; Vinod Chandran; Paula Harvey; Richard J Cook; Dafna D Gladman; Vincent Piguet; Lihi Eder Journal: Arthritis Rheumatol Date: 2022-05-16 Impact factor: 15.483
Authors: Vasiliki-Kalliopi Bournia; George E Fragoulis; Panagiota Mitrou; Konstantinos Mathioudakis; Anastasios Tsolakidis; George Konstantonis; Georgia Vourli; Dimitrios Paraskevis; Maria G Tektonidou; Petros P Sfikakis Journal: RMD Open Date: 2021-11